Welcome to our dedicated page for Edap Tms news (Ticker: EDAP), a resource for investors and traders seeking the latest updates and insights on Edap Tms stock.
EDAP TMS SA (NASDAQ: EDAP) is a global leader in therapeutic ultrasound with over 30 years of experience. The company develops, manufactures, promotes, and distributes minimally-invasive medical devices for urology using advanced ultrasound technology. With a robust presence worldwide through a network of corporate offices, subsidiaries, and distribution partners, EDAP TMS is committed to innovation and excellence.
EDAP TMS operates through three main divisions:
- HIFU (High-Intensity Focused Ultrasound): This division focuses on the development and marketing of devices for the non-invasive destruction of tumors. Key products include Ablatherm, Ablatherm Fusion, and the Focal One, which is the latest addition designed for ideal focal therapy of localized prostate cancer.
- ESWL (Extracorporeal ShockWave Lithotripsy): This division manufactures and services the Sonolith range of lithotripters, which are used for the treatment of kidney stones.
- Distribution: This division markets complementary products such as lasers, micro-ultrasound systems, and other medical devices from third-party suppliers.
EDAP TMS is known for its strong patent portfolio thanks to continuous investment in research and development. The company collaborates with globally acclaimed medical research institutions to push the boundaries of medical technology. Financially, EDAP TMS reported a gross profit of EUR 24.4 million (USD 26.4 million) for the year ending December 31, 2023, reflecting a slight increase from the previous year. However, the gross profit margin declined due to inflationary pressures and investments in U.S. operations to support long-term revenue growth.
Recent achievements include the launch of the Focal One and strategic partnerships to expand its product reach. The company’s commitment to innovation and patient care makes it a significant player in the medical device industry.
EDAP TMS announced notable growth for its Focal One device in the U.S., with installations at five leading healthcare centers, including Brigham and Women’s Hospital and Cedars-Sinai, during Q4 2021.
CEO Marc Oczachowski expressed optimism regarding increased market adoption following a restructuring of U.S. operations.
Ryan Rhodes, CEO of EDAP U.S., highlighted the device's significance in prostate oncology as they enter 2022 with strong momentum.
EDAP TMS SA (Nasdaq: EDAP) announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. The company will engage in investor 1x1 meetings on November 30. A video replay of the fireside chat will be available on EDAP's website post-event. EDAP TMS is recognized for its innovative robotic energy-based therapies, particularly in the therapeutic ultrasound market, with products like the Focal One® and ExactVu™ aimed at prostate cancer treatment.
EDAP TMS SA reported unaudited financial results for Q3 2021, revealing year-to-date revenue of approximately EUR 30.1 million (USD 35.9 million), a 14.4% increase compared to 2020. Q3 revenue remained flat at EUR 9.4 million (USD 11.1 million), impacted by COVID-19 on capital equipment sales. U.S. HIFU treatment volumes rose 58% year-to-date, highlighting strong adoption by urologists. Despite a strong cash position of EUR 45.4 million (USD 52.6 million), Q3 saw a gross profit margin decline to 38.4% due to reduced sales effects on fixed costs. The company will host a conference call on November 18, 2021.
EDAP TMS SA (Nasdaq: EDAP) announced its plans to release third quarter financial results for the period ended September 30, 2021, after market close on November 17, 2021. The company will host a conference call and webcast on November 18, 2021, at 8:30 AM ET, featuring key executives including the CEO and CFO. This event will discuss the financial results and future outlook.
EDAP is recognized for developing minimally invasive medical devices using ultrasound technology for various medical conditions.
EDAP TMS SA (Nasdaq: EDAP) has announced that the University of Washington Medicine will implement the Focal One® high intensity focused ultrasound (HIFU) technology for prostate cancer treatment at its UW Medical Center location. This partnership aims to enhance prostate cancer management through advanced imaging and targeted treatments. Marc Oczachowski, CEO of EDAP, emphasized the global adoption of their technology. The Focal One system offers precise ablation capabilities while minimizing side effects, indicating a significant advancement in prostate cancer care.
EDAP TMS SA (Nasdaq: EDAP) announced data from studies presented at the AUA 2021 Annual Meeting indicating the superiority of High-Intensity Focused Ultrasound (HIFU) over radical prostatectomy for prostate cancer treatment.
The studies revealed that Focal One technology maintained better erectile function and urinary continence, with a salvage-treatment-free survival rate of 97.5% compared to 90.3% for radical prostatectomy. EDAP's advancements in minimally invasive therapies reinforce its position as a leader in the therapeutic ultrasound market.
EDAP TMS announced participation in two September 2021 investor conferences. The H.C. Wainwright 23rd Annual Global Investment Conference will be held virtually from September 13-15, with a presentation accessible from September 13 at 7:00 am ET. The Lake Street’s 5th Annual Best Ideas Growth Conference will occur virtually on September 14-15, featuring one-on-one meetings with institutional investors. EDAP TMS specializes in robotic energy-based therapies, including advanced ultrasound technologies for prostate cancer treatment.
EDAP TMS SA reported a revenue increase of 22.5% for the first half of 2021, totaling EUR 20.7 million (USD 24.8 million). Despite strong growth in U.S. HIFU treatment volumes, the HIFU business revenue declined by 15.1% year-over-year. Net income improved to EUR 0.4 million (USD 0.4 million), compared to a net loss of EUR 1.5 million in the prior year. The CMS advisory panel recommended increasing HIFU reimbursement rates significantly for 2022, which could boost future sales. The company maintained a robust cash balance of EUR 45 million (USD 53.3 million) as of June 30, 2021.
EDAP TMS SA (Nasdaq: EDAP) reported preliminary second quarter 2021 revenue of approximately EUR 10.4 million (USD $12.4 million), an 11.8% increase year-over-year, with first half revenue rising 22.5% to EUR 20.7 million (USD $24.8 million). U.S. High-Intensity Focused Ultrasound (HIFU) treatment volumes surged 79% compared to 2020, signaling strong adoption in the market. The company ended the quarter with cash and cash equivalents of EUR 45 million (USD $53.3 million) and announced the appointment of Ryan Rhodes as CEO of its U.S. subsidiary. A detailed financial report is expected on August 25, 2021.
EDAP TMS SA (Nasdaq: EDAP) announces significant achievements in 2021, including a successful secondary offering that raised approximately $28 million to enhance its U.S. market capabilities. The company has made notable sales to prominent health institutions like Mt. Sinai and Cleveland Clinic. The hiring of Ryan Rhodes as CEO of the U.S. subsidiary aims to accelerate high intensity focused ultrasound (HIFU) adoption in prostate cancer treatment. Additionally, a Category 1 CPT code was established for HIFU reimbursement, effective January 1, 2021.
FAQ
What is the current stock price of Edap Tms (EDAP)?
What is the market cap of Edap Tms (EDAP)?
What does EDAP TMS SA specialize in?
What are the main divisions of EDAP TMS SA?
What products are included in the HIFU division?
What is the function of the ESWL division?
What type of products does the Distribution division market?
What recent achievements has EDAP TMS SA accomplished?
How does EDAP TMS SA support its innovation?
What were the financial results for EDAP TMS SA in 2023?
How does EDAP TMS SA maintain its market position?
Who can be contacted for investor relations at EDAP TMS SA?
